Integra LifeSciences IART Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenues by Product | ||||||
| ENT | $165.28M+0.4% | $166.37M+22.7% | $165.1M+61.2% | $164.82M+132% | $164.65M+333% | |
| Instruments | $202.76M-3.8% | $206.47M+1.1% | $205.21M+0.5% | $209.3M+4.7% | $210.75M+4.5% | |
| Neurosurgery | $834.95M+5.4% | $827.67M+3.0% | $821.56M+3.5% | $795.95M-3.8% | $792.46M-4.2% | |
| Private Label | $113.17M+1.1% | $111.25M-4.4% | $106.06M-12.7% | $110.16M-6.6% | $111.98M+3.3% | |
| Wound Reconstruction | $328.36M-4.7% | $323.49M-7.7% | $345.05M+0.6% | $341.52M-2.6% | $344.47M-2.7% | |
| Total Revenues by Geography | ||||||
| Asia Pacific | $189.36M+10.0% | $189.25M+7.2% | $179.58M+0.5% | $173.96M-8.6% | $172.17M-10.4% | |
| Europe | $167.3M+9.9% | $162.67M+2.6% | $162.66M+0.5% | $154.13M-8.8% | $152.23M-8.2% | |
| Rest of World | $75.94M-6.5% | $78.58M-5.0% | $80.33M-2.8% | $78.91M-6.1% | $81.25M-2.6% | |
| United States | $1.21B-0.6% | $1.2B+1.0% | $1.22B+7.1% | $1.21B+8.5% | $1.22B+12.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Integra LifeSciences break its business down?
- Integra LifeSciences (IART) reports total revenues by business across 2 parts — Specialty Surgery and Tissue Reconstruction. Each is extracted from the segment footnotes and tracked over time.
- Where does Integra LifeSciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Integra LifeSciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
